# US 2020/0392191 A1 · Ompg variants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392191 A1
- Document ID: US20200392191A1
- Status: Published application
- Kind: A1
- Application number: 16/925,848
- Filed: 2020-07-10
- Published: 2020-12-17
- Earliest claimed: 2015-09-22
- Assignees: Roche Sequencing Solutions, Inc.
- Applicants: Roche Sequencing Solutions, Inc.
- Inventors: Cynthia CECH; Tim CRAIG; Christos TZITZILONIS; Alexander YANG; Liv JENSEN; Charlotte YANG; Corissa HARRIS; Matthew DIPIETRO; Dhruti DALAL
- Web page: https://patentgrep.com/patent/US20200392191A1

## CPC

- C07K 14/245: Escherichia (G)
- C12N 9/1252: {DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase}
- C12Q 1/68: involving nucleic acids
- C12Q 1/6874: involving nucleic acid arrays, e.g. sequencing by hybridisation
- C12Y 207/07007: DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
- G01N 33/6803: {General methods of protein analysis not limited to specific proteins or families of proteins}
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure provides variant OmpG polypeptides, compositions comprising the OmpG variant polypeptides, and methods for using the variant OmpG polypeptides as nanopores for determining the sequence of single stranded nucleic acids. The variant OmpG nanopores reduce the ionic current noise versus the parental OmpG polypeptide from which they are derived and thereby enable sequencing of polynucleotides with single nucleotide resolution. The reduced ionic current noise also provides for the use of these OmpG nanopore variants in other single molecule sensing applications, e.g., protein sequencing.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A circular permutation variant of a parental outer membrane protein G (OmpG) polypeptide, wherein the parental OmpG polypeptide comprises an amino acid sequence having at least 95% sequence identity to one or more amino acid sequences selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 5-11, wherein the circular permutation variant is capable of forming a nanopore.

### Claim 17 (depends on 16)

The circular permutation variant of claim 16, wherein the parental OmpG polypeptide comprises a deletion of one or more loop-6 amino acids.

### Claim 18 (depends on 17)

The circular permutation variant of claim 17, wherein the parental OmpG polypeptide further comprises a substitution at position Y50 relative to a polypeptide consisting of SEQ ID NO: 2 and/or deletion of D215 relative to a polypeptide consisting of SEQ ID NO: 2.

### Claim 19 (depends on 18)

The circular permutation variant of claim 18, wherein the parental OmpG polypeptide comprises the amino acid sequence having at least 95% sequence identity to SEQ ID NO: 5, with the proviso that said amino acid sequence comprises the deletion of one or more loop-6 amino acids, a deletion of amino acid D215 of SEQ ID NO: 5, and an A217 amino acid residue of SEQ ID NO: 5.

### Claim 20 (depends on 19)

The circular permutation variant of claim 19, further comprising a mutation of one or more of amino acids R211, E15, R68, Y50, E152, E174, E17, D215, K114, E174, F66, or E31 of SEQ ID NO: 5.

### Claim 21 (depends on 20)

The circular permutation variant of claim 20, wherein the mutation comprises one or more of a R211N, R68N, Y50K, Y50N, or E17K mutation of SEQ ID NO: 5.

### Claim 22 (depends on 21)

The circular permutation variant of claim 21, wherein the mutation of SEQ ID NO: 5 is a Y50K amino acid substitution.

### Claim 23 (depends on 18)

The circular permutation variant of claim 18, wherein the parental OmpG polypeptide comprises the amino acid sequence having at least 95% sequence identity to SEQ ID NO: 5, with the proviso that said amino acid sequence comprises the deletion of one or more loop-6 amino acids, a Y50K or Y50N amino acid substitution of SEQ ID NO: 5, and an A217 amino acid residue of SEQ ID NO: 5.

### Claim 24 (depends on 23)

The circular permutation variant of claim 23, further comprising a mutation of one or more of amino acids R211, E15, R68, E152, E174, E17, D215, K114, E174, F66, or E31 of SEQ ID NO:2.

### Claim 25 (depends on 24)

The circular permutation variant of claim 24, wherein the mutation is a D215 deletion of SEQ ID NO: 5.

### Claim 26 (depends on 24)

The circular permutation variant of claim 24, wherein the mutation comprises one or more of a R211N or R68N mutations of SEQ ID NO: 5.

### Claim 27 (depends on 16)

The circular permutation variant of claim 16, wherein the circular permutation variant has at least 95% sequence identity with SEQ ID NO: 17.

### Claim 28

A variant outer membrane protein G (OmpG) polypeptide comprising an amino acid sequence having at least 90% sequence identity to at least one of SEQ ID NO: 12-15, wherein the variant retains the ability to form a nanopore.

### Claim 29 (depends on 28)

The variant OmpG polypeptide of claim 28, wherein the amino acid sequence further comprises a deletion of at least one loop-6 amino acids.

### Claim 30 (depends on 29)

The variant OmpG polypeptide of claim 29, wherein the deletion of at least one loop-6 amino acids corresponds to a deletion of each of amino acids 216-227 of SEQ ID NO:2 when the amino acid sequence is aligned with SEQ ID NO: 2.

### Claim 31 (depends on 29)

The variant OmpG polypeptide of claim 29, wherein the amino acid sequence further comprises a mutation of one or more of amino acids R211, E15, R68, Y50, E152, E174, E17, D215, K114, E174, F66, or E31 of SEQ ID NO: 5 when the amino acid sequence is aligned with SEQ ID NO: 5.

### Claim 32 (depends on 31)

The variant OmpG polypeptide of claim 31, wherein the mutation comprises one or more of a R211N, R68N, Y50K, Y50N, or E17K mutation of SEQ ID NO: 5.

### Claim 33 (depends on 32)

The variant OmpG polypeptide of claim 32, wherein the mutation of SEQ ID NO: 5 is a Y50K amino acid substitution.

### Claim 34 (depends on 31)

The variant OmpG polypeptide of claim 31, wherein the mutation is a D215 deletion of SEQ ID NO: 5.

### Claim 35 (depends on 28)

The variant OmpG polypeptide of claim 28, wherein the amino acid sequence comprises a Y50K amino acid substitution and an A217 amino acid residue when aligned with SEQ ID NO: 5.

### Claim 36 (depends on 28)

The variant OmpG polypeptide of claim 28, wherein the amino acid sequence comprises a deletion of D215 and an A217 amino acid residue when aligned with SEQ ID NO: 5.
